Anticholinergic drugs in late life

adverse effects on cognition but not on progress to dementia

Lawrence J. Whalley, Sumit Sharma, Helen C. Fox, Alison D. Murray, Roger T. Staff, Ashleigh C. Duthie, Ian J. Deary, John M. Starr

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Impaired cognitive function associated with use of anticholinergic drugs may be partly attributed to underlying physical illness and exposure to factors that increase the risk of some physical disorders such as low socioeconomic status (SES) and less education. To estimate the extent of cognitive impairment and risk of progress to dementia associated with anticholinergic drug use and to estimate confounding by gender, APOE, family history of dementia, lower SES, less education, and lower childhood mental ability, we recruited 281 volunteers at age 77-78 without overt dementia who had taken part in the Scottish Mental Survey of 1932. Clinical histories, use of medications, self reported frequency of emotional symptoms and standardized tests of cognitive function were obtained. With and without adjustment for age and childhood IQ, there were significant between-group differences in tests of non-verbal reasoning and spatial ability. During 10 year follow-up, progress to overt dementia was not associated with anticholinergic drugs use on recruitment but female gender and a history of dementia in parent or sibling were associated with dementia. We concluded that anticholinergic drug use in this narrow age range sample was linked to cognitive impairment but not to subsequent dementia.
Original languageEnglish
Pages (from-to)253-261
Number of pages9
JournalJournal of Alzheimer's Disease
Volume30
Issue number2
Early online date16 Mar 2012
DOIs
Publication statusPublished - May 2012

Fingerprint

Cholinergic Antagonists
Cognition
Dementia
Pharmaceutical Preparations
Social Class
Education
Aptitude
Ego
Siblings
Volunteers

Keywords

  • cholinergic antagonists
  • humans
  • Alzheimer disease
  • disease progression
  • aged
  • apolipoproteins E
  • longitudinal studies
  • cognition
  • cognition disorders
  • socioeconomic factors
  • Scotland
  • intelligence
  • aged, 80 and over
  • risk factors
  • cohort studies
  • follow-up studies
  • sex distribution
  • male
  • female

Cite this

Anticholinergic drugs in late life : adverse effects on cognition but not on progress to dementia. / Whalley, Lawrence J.; Sharma, Sumit; Fox, Helen C.; Murray, Alison D.; Staff, Roger T.; Duthie, Ashleigh C.; Deary, Ian J.; Starr, John M.

In: Journal of Alzheimer's Disease, Vol. 30, No. 2, 05.2012, p. 253-261.

Research output: Contribution to journalArticle

Whalley, Lawrence J. ; Sharma, Sumit ; Fox, Helen C. ; Murray, Alison D. ; Staff, Roger T. ; Duthie, Ashleigh C. ; Deary, Ian J. ; Starr, John M. / Anticholinergic drugs in late life : adverse effects on cognition but not on progress to dementia. In: Journal of Alzheimer's Disease. 2012 ; Vol. 30, No. 2. pp. 253-261.
@article{1c0b9d4971814f4c810442581cbb26d5,
title = "Anticholinergic drugs in late life: adverse effects on cognition but not on progress to dementia",
abstract = "Impaired cognitive function associated with use of anticholinergic drugs may be partly attributed to underlying physical illness and exposure to factors that increase the risk of some physical disorders such as low socioeconomic status (SES) and less education. To estimate the extent of cognitive impairment and risk of progress to dementia associated with anticholinergic drug use and to estimate confounding by gender, APOE, family history of dementia, lower SES, less education, and lower childhood mental ability, we recruited 281 volunteers at age 77-78 without overt dementia who had taken part in the Scottish Mental Survey of 1932. Clinical histories, use of medications, self reported frequency of emotional symptoms and standardized tests of cognitive function were obtained. With and without adjustment for age and childhood IQ, there were significant between-group differences in tests of non-verbal reasoning and spatial ability. During 10 year follow-up, progress to overt dementia was not associated with anticholinergic drugs use on recruitment but female gender and a history of dementia in parent or sibling were associated with dementia. We concluded that anticholinergic drug use in this narrow age range sample was linked to cognitive impairment but not to subsequent dementia.",
keywords = "cholinergic antagonists, humans, Alzheimer disease, disease progression, aged, apolipoproteins E, longitudinal studies, cognition, cognition disorders, socioeconomic factors, Scotland, intelligence, aged, 80 and over, risk factors, cohort studies, follow-up studies, sex distribution, male, female",
author = "Whalley, {Lawrence J.} and Sumit Sharma and Fox, {Helen C.} and Murray, {Alison D.} and Staff, {Roger T.} and Duthie, {Ashleigh C.} and Deary, {Ian J.} and Starr, {John M.}",
year = "2012",
month = "5",
doi = "10.3233/JAD-2012-110935",
language = "English",
volume = "30",
pages = "253--261",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Anticholinergic drugs in late life

T2 - adverse effects on cognition but not on progress to dementia

AU - Whalley, Lawrence J.

AU - Sharma, Sumit

AU - Fox, Helen C.

AU - Murray, Alison D.

AU - Staff, Roger T.

AU - Duthie, Ashleigh C.

AU - Deary, Ian J.

AU - Starr, John M.

PY - 2012/5

Y1 - 2012/5

N2 - Impaired cognitive function associated with use of anticholinergic drugs may be partly attributed to underlying physical illness and exposure to factors that increase the risk of some physical disorders such as low socioeconomic status (SES) and less education. To estimate the extent of cognitive impairment and risk of progress to dementia associated with anticholinergic drug use and to estimate confounding by gender, APOE, family history of dementia, lower SES, less education, and lower childhood mental ability, we recruited 281 volunteers at age 77-78 without overt dementia who had taken part in the Scottish Mental Survey of 1932. Clinical histories, use of medications, self reported frequency of emotional symptoms and standardized tests of cognitive function were obtained. With and without adjustment for age and childhood IQ, there were significant between-group differences in tests of non-verbal reasoning and spatial ability. During 10 year follow-up, progress to overt dementia was not associated with anticholinergic drugs use on recruitment but female gender and a history of dementia in parent or sibling were associated with dementia. We concluded that anticholinergic drug use in this narrow age range sample was linked to cognitive impairment but not to subsequent dementia.

AB - Impaired cognitive function associated with use of anticholinergic drugs may be partly attributed to underlying physical illness and exposure to factors that increase the risk of some physical disorders such as low socioeconomic status (SES) and less education. To estimate the extent of cognitive impairment and risk of progress to dementia associated with anticholinergic drug use and to estimate confounding by gender, APOE, family history of dementia, lower SES, less education, and lower childhood mental ability, we recruited 281 volunteers at age 77-78 without overt dementia who had taken part in the Scottish Mental Survey of 1932. Clinical histories, use of medications, self reported frequency of emotional symptoms and standardized tests of cognitive function were obtained. With and without adjustment for age and childhood IQ, there were significant between-group differences in tests of non-verbal reasoning and spatial ability. During 10 year follow-up, progress to overt dementia was not associated with anticholinergic drugs use on recruitment but female gender and a history of dementia in parent or sibling were associated with dementia. We concluded that anticholinergic drug use in this narrow age range sample was linked to cognitive impairment but not to subsequent dementia.

KW - cholinergic antagonists

KW - humans

KW - Alzheimer disease

KW - disease progression

KW - aged

KW - apolipoproteins E

KW - longitudinal studies

KW - cognition

KW - cognition disorders

KW - socioeconomic factors

KW - Scotland

KW - intelligence

KW - aged, 80 and over

KW - risk factors

KW - cohort studies

KW - follow-up studies

KW - sex distribution

KW - male

KW - female

U2 - 10.3233/JAD-2012-110935

DO - 10.3233/JAD-2012-110935

M3 - Article

VL - 30

SP - 253

EP - 261

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 2

ER -